Evidence map›Paper›PMID 20807808›Full record

Trial reportCancer research2010

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Meng-Lei Zhu, Craig M Horbinski, Mark Garzotto, David Z Qian, Tomasz M Beer, Natasha Kyprianou

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 2 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 2 syntheses or guidelines pooled it, 350 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Expression of AR-V7 and ARvClinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  16. Computational analysis of treatment resistant cancer cells.Frontiers in cell and developmental biology · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Meng-Lei ZhuDepartments of Toxicology, Pathology, Molecular Biochemistry, and Urology, University of Kentucky College of Medicine, Lexington, Kentucky 40536, USA.
Craig M Horbinski
Mark Garzotto
David Z Qian
Tomasz M Beer
Natasha Kyprianou
Oregon Health & Science University · USUniversity of Kentucky · US

Funding

The study of Gpr149 in nociception and the peripheral action of minor cannabinoidsR01AT010757 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HELLMAN, JUDITH, SCHUMACHER, MARK A · 2019 to 2023
$3.0M
Anoikis Effect by Quinazolines on Prostate GrowthR01CA107575 · NCI · UNIVERSITY OF KENTUCKY · PI KYPRIANOU, NATASHA · 2004 to 2008
$1.2M
NCCIH NIH HHS R01 AT010757NCI NIH HHS R01 CA10757-05NCI NIH HHS R01 CA107575
6 · The paper itself

Abstract

Recent insights into the regulation of the androgen receptor (AR) activity led to novel therapeutic targeting of AR function in prostate cancer patients. Docetaxel is an approved chemotherapy for treatment of castration-resistant prostate cancer; however, the mechanism underlying the action of this tubulin-targeting drug is not fully understood. This study investigates the contribution of microtubules and the cytoskeleton to androgen-mediated signaling and the consequences of their inhibition on AR activity in human prostate cancer. Tissue microarrays from docetaxel-treated and untreated prostate cancer patients were comparatively analyzed for prostate-specific antigen (PSA) and AR immunoreactivity. The AR transcriptional activity was determined in prostate cancer cells in vitro, based on PSA mRNA expression and the androgen response element reporter activity. The interaction of AR with tubulin was examined by immunoprecipitation and immunofluorescence. Treatment of prostate cancer patients with docetaxel led to a significant translocation of AR. In untreated specimens, 50% prostate tumor cells exhibited nuclear accumulation of AR, compared with docetaxel-treated tumors that had significantly depleted nuclear AR (38%), paralleled by an increase in cytosolic AR. AR nuclear localization correlated with PSA expression. In vitro, exposure of prostate cancer cells to paclitaxel (1 μmol/L) or nocodazole (5 μg/mL) inhibited androgen-dependent AR nuclear translocation by targeting AR association with tubulin. Introduction of a truncated AR indicated the requirement of the NH(2)-terminal domain for AR-tubulin interaction. Our findings show that in addition to blocking cell division, docetaxel impairs AR signaling, evidence that enables new insights into the therapeutic efficacy of microtubule-targeting drugs in prostate cancer.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDocetaxelGene Expression Regulation, NeoplasticHumansMaleMicroarray AnalysisMitoxantroneProstate-Specific AntigenProstatic NeoplasmsReceptors, AndrogenReference ValuesReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmTaxoidsAntineoplastic AgentsDocetaxelMitoxantroneProstate-Specific AntigenReceptors, AndrogenRNA, NeoplasmTaxoidsTubulin

Identifiers

PMID20807808
PMCPMC2978028
OpenAlexW2075004958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.